{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:49:32Z","timestamp":1781304572141,"version":"3.54.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic lupus erythematosus (SLE) is associated with increased risk of cancer and the mechanism remains unclear. Here, we examined the level of auto-antibodies and disease activity index scores in SLE patients with cancers and analyzed whether medications for SLE management might contribute to the higher cancer risk in SLE patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, we carried out a nested case-control study in a large cohort of SLE patients. We screened 5858 SLE patients to identify the newly diagnosed and yet to be treated cancers. The following clinical features were evaluated: auto-antibodies levels, SLE disease activity index scores, and previous medication used for SLE management. Systemic glucocorticoid, cyclophosphamide, hydroxychloroquine (HCQ), methotrexate, and azathioprine were considered the main medication indices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analyses identified 51 SLE patients who also had cancer and 204 matched control patients who had SLE but not cancer. Of the 51 SLE patients, thyroid cancer (14\/51, 27.45%), cervical cancer (10\/51, 19.61%), and lung cancer (7\/51, 13.73%) were the most common types. Our analyses did not reveal any significant differences in the levels of auto-antibodies in SLE patients with cancers relative to the control group. Further, we observed that disease activity was significantly lower in SLE patients with cancers relative to the matched control SLE group. There was no statistically significant association between the cancer risk and the use of systemic glucocorticoid, cyclophosphamide, methotrexate, or azathioprine. Importantly, the administration of HCQ was significantly lower in SLE patients suffering cancers relative to the cancer-free matched control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analyses indicate that SLE patients with cancers might have a lower disease activity at the time of cancer diagnosis. HCQ was negatively associated with cancer risk in SLE patients. These findings highlight a potential and novel prevention strategy for SLE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-020-02228-6","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T21:02:43Z","timestamp":1593118963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The relationship between cancer and medication exposure in patients with systemic lupus erythematosus: a nested case-control study"],"prefix":"10.1186","volume":"22","author":[{"given":"Jinyan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zujiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"8","key":"2228_CR1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.autrev.2011.10.021","volume":"11","author":"OP Rekvig","year":"2012","unstructured":"Rekvig OP, Putterman C, Casu C, et al. Autoantibodies in lupus: culprits or passive bystanders? Autoimmun Rev. 2012;11(8):596\u2013603.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"2228_CR2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/art.21029","volume":"52","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52(5):1481\u201390.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2228_CR3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1136\/ard.51.4.437","volume":"51","author":"T Pettersson","year":"1992","unstructured":"Pettersson T, Pukkala E, Teppo L, et al. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis. 1992;51(4):437\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2228_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/03009740252937568","volume":"31","author":"L Bj\u00f6rn\u00e5dal","year":"2002","unstructured":"Bj\u00f6rn\u00e5dal L, L\u00f6fstr\u00f6m B, Yin L, et al. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol. 2002;31(2):66\u201371.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"2228_CR5","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.1780400424","volume":"40","author":"L Mellemkjaer","year":"1997","unstructured":"Mellemkjaer L, Andersen V, Linet MS, et al. Non-Hodgkin\u2019s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(4):761\u20138.","journal-title":"Arthritis Rheum"},{"key":"2228_CR6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2012.12.009","volume":"42","author":"S Bernatsky","year":"2013","unstructured":"Bernatsky S, Ramsey-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013;42:130\u20135.","journal-title":"J Autoimmun"},{"issue":"12","key":"2228_CR7","first-page":"1150.e1151","volume":"123","author":"YJ Chen","year":"2010","unstructured":"Chen YJ, Chang YT, Wang CB, et al. Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med. 2010;123(12):1150.e1151\u20136.","journal-title":"Am J Med"},{"issue":"5","key":"2228_CR8","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/ard.61.5.409","volume":"61","author":"KE Moss","year":"2002","unstructured":"Moss KE, Ioannou Y, Sultan SM, et al. Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades. Ann Rheum Dis. 2002;61(5):409\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2228_CR9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","volume":"15","author":"G Ruiz-Irastorza","year":"2006","unstructured":"Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15(9):577\u201383.","journal-title":"Lupus."},{"issue":"2","key":"2228_CR10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.rdc.2005.01.002","volume":"31","author":"S Bernatsky","year":"2005","unstructured":"Bernatsky S, Ramsey-Goldman R, Clarke A. Exploring the links between systemic lupus erythematosus and cancer. Rheum Dis Clin North Am. 2005;31(2):387\u2013402, viii-ix.","journal-title":"Rheum Dis Clin North Am"},{"issue":"3","key":"2228_CR11","first-page":"113","volume":"57","author":"A Imran","year":"2003","unstructured":"Imran A, Neelam F, Tariq M. Incidence of circulating antinuclear antibodies in cancer patients. Indian J Med Sci. 2003;57(3):113\u20136.","journal-title":"Indian J Med Sci"},{"issue":"4","key":"2228_CR12","doi-asserted-by":"crossref","first-page":"16546","DOI":"10.4238\/2015.December.11.1","volume":"14","author":"HY Zou","year":"2015","unstructured":"Zou HY, Gu X, Yu WZ, et al. Detection of serum antinuclear antibodies in lymphoma patients. Genet Mol Res. 2015;14(4):16546\u201352.","journal-title":"Genet Mol Res"},{"issue":"8","key":"2228_CR13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1471-4906(01)01984-6","volume":"22","author":"VP Torchilin","year":"2001","unstructured":"Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol. 2001;22(8):424\u20137.","journal-title":"Trends Immunol"},{"issue":"2","key":"2228_CR14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.imlet.2005.03.019","volume":"99","author":"S Lv","year":"2005","unstructured":"Lv S, Zhang J, Wu J, et al. Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. Immunol Lett. 2005;99(2):217\u201327.","journal-title":"Immunol Lett"},{"key":"2228_CR15","first-page":"4351","volume":"20","author":"KN Syrigos","year":"2000","unstructured":"Syrigos KN, Charalambopoulos A, Pliarchopoulou K, et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res. 2000;20:4351\u20133.","journal-title":"Anticancer Res"},{"issue":"6","key":"2228_CR16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/annonc\/mdv104","volume":"26","author":"P Mitchell","year":"2015","unstructured":"Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol. 2015;26(6):1134\u201342.","journal-title":"Ann Oncol"},{"issue":"1","key":"2228_CR17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1468-3083.2011.04364.x","volume":"27","author":"C Maire","year":"2013","unstructured":"Maire C, Vercambre-Darras S, Devos P, et al. Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. J Eur Acad Dermatol Venereol. 2013;27(1):92\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2228_CR18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.2006.069039","volume":"67","author":"S Bernatsky","year":"2008","unstructured":"Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis. 2008;67(1):74\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2228_CR19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/annrheumdis-2012-202099","volume":"73","author":"S Bernatsky","year":"2014","unstructured":"Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2228_CR20","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1136\/ard.2006.067108","volume":"66","author":"B L\u00f6fstr\u00f6m","year":"2007","unstructured":"L\u00f6fstr\u00f6m B, Backlin C, Sundstr\u00f6m C, et al. A closer look at non-Hodgkin\u2019s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study. Ann Rheum Dis. 2007;66(12):1627\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2228_CR21","first-page":"620","volume":"56","author":"CY Hsu","year":"2017","unstructured":"Hsu CY, Lin MS, SuYJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56(4):620\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"2228_CR22","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2228_CR23","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35(6):630\u201340.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2228_CR24","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0961203316688783","volume":"26","author":"G Singh","year":"2017","unstructured":"Singh G, Agarwal AK, Prosek J, et al. Can killers be saviors? Lupus. 2017;26(9):903\u20138.","journal-title":"Lupus."},{"key":"2228_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2018.05.002","volume":"127","author":"A Vlagea","year":"2018","unstructured":"Vlagea A, Falagan S, Guti\u00e9rrez-Guti\u00e9rrez G, et al. Antinuclear antibodies and cancer: a literature review. Crit Rev Oncol Hematol. 2018;127:42\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"2228_CR26","first-page":"451","volume":"177","author":"H Dellen","year":"1983","unstructured":"Dellen H, Seemayer NH. Autoimmunity in patients with bronchogenic carcinomas: occurrence of antibodies against nuclear antigens, chromosomes and ds-deoxyribonucleic acid. Zentralbl Bakteriol Mikrobiol Hyg B. 1983;177(6):451\u201368.","journal-title":"Zentralbl Bakteriol Mikrobiol Hyg B"},{"issue":"7","key":"2228_CR27","first-page":"781","volume":"31","author":"SM Attar","year":"2010","unstructured":"Attar SM, Koshak EA. Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid. Saudi Med J. 2010;31(7):781\u20137.","journal-title":"Saudi Med J"},{"issue":"3","key":"2228_CR28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","volume":"39","author":"D Gladman","year":"1996","unstructured":"Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39(3):363\u20139.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2228_CR29","first-page":"1977","volume":"30","author":"D Iba\u00f1ez","year":"2003","unstructured":"Iba\u00f1ez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol. 2003;30(9):1977\u201382.","journal-title":"J Rheumatol"},{"issue":"6","key":"2228_CR30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0961203309102556","volume":"18","author":"M Gayed","year":"2009","unstructured":"Gayed M, Bernatsky S, Ramsey-Goldman R, et al. Lupus and cancer. Lupus. 2009;18(6):479\u201385.","journal-title":"Lupus"},{"key":"2228_CR31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.leukres.2018.11.004","volume":"75","author":"A Klein","year":"2018","unstructured":"Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: incidence, pathogenesis and biology. Leuk Res. 2018;75:45\u20139.","journal-title":"Leuk Res"},{"issue":"7","key":"2228_CR32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/kez088","volume":"58","author":"M Schmalzing","year":"2019","unstructured":"Schmalzing M. The relationship of lymphoma and lupus-at least bidirectional. Rheumatology. 2019;58(7):1131\u20132.","journal-title":"Rheumatology"},{"issue":"9","key":"2228_CR33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","volume":"66","author":"GS Alarc\u00f3n","year":"2007","unstructured":"Alarc\u00f3n GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168\u201372.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2228_CR34","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1002\/art.34672","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Purvey S, Fang H, et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum. 2012;64(12):4021\u20138.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2228_CR35","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/ard.2006.067777","volume":"66","author":"G Ruiz-Irastorza","year":"2007","unstructured":"Ruiz-Irastorza G, Ugarte A, Egurbide MV, et al. Antimalarials may influence the risk of malignancy in systemic lupus erythematosus. Ann Rheum Dis. 2007;66(6):815\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2228_CR36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc3262","volume":"12","author":"E White","year":"2012","unstructured":"White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401\u201310.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2228_CR37","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/carcin\/23.6.949","volume":"23","author":"TA Sohn","year":"2002","unstructured":"Sohn TA, Bansal R, Su GH, et al. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002;23(6):949\u201357.","journal-title":"Carcinogenesis."},{"issue":"5","key":"2228_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","volume":"144","author":"J Sotelo","year":"2006","unstructured":"Sotelo J, Brice\u00f1o E, L\u00f3pez-Gonz\u00e1lez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144(5):337\u201343.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2228_CR39","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3171\/foc.2003.14.2.4","volume":"14","author":"E Brice\u00f1o","year":"2003","unstructured":"Brice\u00f1o E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 2003;14(2):e3.","journal-title":"Neurosurg Focus"},{"issue":"4","key":"2228_CR40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","volume":"17","author":"RK Amaravadi","year":"2011","unstructured":"Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654\u201366.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2228_CR41","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1158\/1078-0432.CCR-13-3227","volume":"20","author":"KL Cook","year":"2014","unstructured":"Cook KL, W\u00e4rri A, Soto-Pantoja DR, et al. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res. 2014;20(12):3222\u201332.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2228_CR42","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/carcin\/bgt063","volume":"34","author":"J Li","year":"2013","unstructured":"Li J, Yang B, Zhou Q, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis. 2013;34(6):1343\u201351.","journal-title":"Carcinogenesis."},{"issue":"9","key":"2228_CR43","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.4161\/auto.29961","volume":"10","author":"A Yang","year":"2014","unstructured":"Yang A, Kimmelman AC. Inhibition of autophagy attenuates pancreatic cancer growth independent of TP53\/TRP53 status. Autophagy. 2014;10(9):1683\u20134.","journal-title":"Autophagy"},{"issue":"7","key":"2228_CR44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/15680096113139990088","volume":"13","author":"GV Helgason","year":"2013","unstructured":"Helgason GV, Mukhopadhyay A, Karvela M, et al. Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. Curr Cancer Drug Targets. 2013;13(7):724\u201334.","journal-title":"Curr Cancer Drug Targets"},{"issue":"10","key":"2228_CR45","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-10-0890","volume":"17","author":"Y Pan","year":"2011","unstructured":"Pan Y, Gao Y, Chen L, et al. Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy. Clin Cancer Res. 2011;17(10):3248\u201358.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2228_CR46","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-11-0047","volume":"10","author":"ZJ Yang","year":"2011","unstructured":"Yang ZJ, Chee CE, Huang S, et al. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10(9):1533\u201341.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2228_CR47","first-page":"613","volume":"56","author":"H Wadstr\u00f6m","year":"2017","unstructured":"Wadstr\u00f6m H, Arkema EV, Sj\u00f6wall C, et al. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford). 2017;56(4):613\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2228_CR48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","volume":"13","author":"E Zard","year":"2014","unstructured":"Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev. 2014;13(7):730\u20135.","journal-title":"Autoimmun Rev"},{"issue":"11","key":"2228_CR49","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1002\/art.20616","volume":"50","author":"LS Tam","year":"2004","unstructured":"Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum. 2004;50(11):3619\u201325.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02228-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02228-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T20:04:32Z","timestamp":1624651472000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02228-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2228"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02228-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21461\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21461\/v1","asserted-by":"object"}]},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]},"assertion":[{"value":"16 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethical Committee of the First Affiliated Hospital of Zhengzhou University, ethical approval number no.2019-KY-199.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}